311 related articles for article (PubMed ID: 18930255)
1. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C; Harnett M; Dobs AS; Swerdloff RS
J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
[TBL] [Abstract][Full Text] [Related]
4. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
5. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
Saad F; Kamischke A; Yassin A; Zitzmann M; Schubert M; Jockenhel F; Behre HM; Gooren L; Nieschlag E
Asian J Androl; 2007 May; 9(3):291-7. PubMed ID: 17486268
[TBL] [Abstract][Full Text] [Related]
6. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
Moisey R; Swinburne J; Orme S
Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
[TBL] [Abstract][Full Text] [Related]
7. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
9. Oral testosterone replacement in Korean patients with PADAM.
Hong JH; Ahn TY
Aging Male; 2002 Mar; 5(1):52-6. PubMed ID: 12040976
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.
Ho CC; Tong SF; Low WY; Ng CJ; Khoo EM; Lee VK; Zainuddin ZM; Tan HM
BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057
[TBL] [Abstract][Full Text] [Related]
11. Testosterone improves erectile function in hypogonadal patients with venous leakage.
Kurbatov D; Kuznetsky J; Traish A
J Androl; 2008; 29(6):630-7. PubMed ID: 18599885
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
13. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
14. Testosterone supplementation for hypogonadal men by the nasal route.
Mattern C; Hoffmann C; Morley JE; Badiu C
Aging Male; 2008 Dec; 11(4):171-8. PubMed ID: 19172548
[TBL] [Abstract][Full Text] [Related]
15. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
Meikle AW; Matthias D; Hoffman AR
BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
Yassin AA; Saad F
Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with Andriol Testocaps--the first Austrian surveillance study on the treatment of late-onset hypogonadism.
Jungwirth A; Plas E; Geurts P
Aging Male; 2007 Dec; 10(4):183-7. PubMed ID: 18033627
[TBL] [Abstract][Full Text] [Related]
18. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
[TBL] [Abstract][Full Text] [Related]
19. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate.
Minnemann T; Schubert M; Hübler D; Gouni-Berthold I; Freude S; Schumann C; Oettel M; Ernst M; Mellinger U; Sommer F; Krone W; Jockenhövel F
Aging Male; 2007 Sep; 10(3):155-8. PubMed ID: 17701659
[TBL] [Abstract][Full Text] [Related]
20. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]